First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress

Lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present with the advanced stage of the disease at the time of diagnosis, and thus decrease the 5-year survival rate to about 5%. Immu...

Full description

Bibliographic Details
Main Authors: Zhangfeng Huang, Wenhao Su, Tong Lu, Yuanyong Wang, Yanting Dong, Yi Qin, Dahai Liu, Lili Sun, Wenjie Jiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Pharmacology
Subjects:
first-line
PD-L1
immunotherapy
checkpoints
non-small cell lung cancer
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.578091/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.578091/full

Similar Items